Navigation Links
Aegis Awarded 2nd Patent for Fast Acting Migraine Nasal Spray Treatment
Date:5/14/2013

SAN DIEGO, May 14, 2013 /PRNewswire-iReach/ -- Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,440,631, its second patent providing fast acting formulations for triptans, a class of drugs that are effective in treating migraine headaches which include sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan. Human clinical trials have shown that the Intravail® formulation of sumatriptan achieves therapeutic drug levels at approximately 2 to 3 minutes, 20 to 30 times faster that the currently marketed non-injectable sumatriptan products. For comparison, the most widely used triptan formulations, namely sumatriptan nasal spray or tablet formulations, both reach maximum blood levels of drug in about 60 to 120 minutes thus delaying onset of relief.

The enabling Aegis Intravail formulation technology is broadly applicable to a wide range of small molecule and biotherapeutic drugs to increase noninvasive bioavailability by the oral, nasal, buccal, and sublingual routes and to speed attainment of therapeutic drug levels in cases where speed is important to the patient, for example in the treatment of pain, nausea, emesis, convulsive disorders, spasticity, and the like.

Aegis technology is commercialized by our licensees who conduct the actual product development and marketing activities. Aegis' licensees include four of the top 10 largest pharmaceutical companies and two of the top 10 largest generics companies, along with many public and private biotech companies. Aegis growing patent portfolio currently has more than fifty issued and pending drug formulation patents covering peptide, protein, and small-molecule drugs.

About Aegis Therapeutics 
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants.

For more information about Aegis, please visit: http://www.aegisthera.com.

Press release submitted by Submit Press Release 123.com's press release distribution service

Media Contact:   Ralph Barry , Aegis Therapeutics LLC, 858 618-1400 Ext 102, rbarry@aegisthera.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Aegis Therapeutics LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
2. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
3. BidMed Awarded Equipment Liquidation and Related Services Agreement with the Premier Healthcare Alliance
4. Instrumentation Laboratory Awarded Massachusetts Life Sciences Center Tax Incentive
5. Dr. Isaac Eliaz Awarded Patent for Modified Citrus Pectin and Alginates
6. Creabilis Awarded Prestigious European Commission FP7 Grant to Further Develop its LSE Topical-by-Design Technology
7. Combat Medical Systems Awarded $86 Million DOD Contract
8. Remedium Technologies Inc. Awarded $500,000 Phase II NSF SBIR Grant to Test Sprayable Foam for Stopping Traumatic Bleeding
9. CCS Medical Awarded Medicare Contract
10. GE alliance awarded contract to design new plant-based manufacturing facility in Brazil
11. Hadasit Bio-Holdings Flagship Portfolio Company Enlivex Awarded Orphan Drug Status for ApoCell Treatment by the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... MARLBOROUGH, Mass., May 10, 2017 Hologic, Inc. ... financial results for the fiscal second quarter ended April ... (EPS) of $1.84 increased 666.7% compared to the prior ... business resulted in a significant gain, while non-GAAP diluted ... increased 3.2%, or 3.8% in constant currency terms.  Excluding ...
(Date:5/10/2017)... Md. , May 10, 2017 CSSi, ... solutions for the clinical research industry, is proud to ... www.CSSiEnroll.com . The new website features both enriched content ... user experience and enhances the company,s already well-established position ... industry. "After many months of hard ...
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring of several ... had left education officials with a number of critical issues to address before students ... to be accomplished with little or no disruption to class schedules. Second, the project ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, success depends ... instruments for research and understanding the basic principles that were designed to drive ... innovations in stereo microscopy for brightfield and fluorescence typically used in laboratories working ...
(Date:5/24/2017)... ... 24, 2017 , ... Altec Products, Inc., a leader in enterprise ... one-day technology conference in San Diego, CA. , At nVerge 2017, Altec will ... utilize and enhance their Sage ERP solutions by providing improved visibility and control to ...
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. ... NY, who have now spent 10 years as clinical instructors for the reputable ... College of Dentistry. Through the program, private practitioners receive cutting-edge clinical training and ...
(Date:5/24/2017)... ... , ... Patients who want to receive cosmetic dentistry procedures such as Invisalign® ... for a consultation, with or without a referral. Dr. Bedich enjoys improving the appearance ... , Dr. Bedich offers a variety of cosmetic dentistry services at his practice that ...
Breaking Medicine News(10 mins):